Imunon (IMNN)
NASDAQ:IMNN
IMNN Stock Chart & Stats
$2.96
-$0.06(-6.43%)
At close: 4:00 PM EST
$2.96
-$0.06(-6.43%)
Day’s Range― - ―
52-Week Range$2.52 - $41.22
Previous CloseN/A
Volume151.93K
Average Volume (3M)147.02K
Market Cap
$11.61M
Enterprise Value$42.74K
Total Cash (Recent Filing)$8.78M
Total Debt (Recent Filing)$1.01M
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding3,922,764
10 Day Avg. Volume33,528
30 Day Avg. Volume147,022
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.50Price Target Upside525.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker StrategyTargeting a biomarker-positive patient subgroup could enable a more efficient path to topline results and a regulatory filing by focusing on patients most likely to benefit.
Clinical EfficacyPhase 2 OVATION 2 showed a substantial overall survival benefit for newly diagnosed advanced ovarian cancer patients treated with IMNN-001 plus standard therapy, supporting strong clinical differentiation and potential demand for IMNN-001 in frontline treatment.
Trial Design And EnrollmentPhase 3 OVATION 3 enrollment progressing ahead of internal forecasts, supported by a global CRO and top treatment centers, combined with an adaptive design and interim analyses, could allow earlier efficacy readouts and strengthen a regulatory submission if outcomes are favorable.
Bears Say
Dependence On External Funding ArrangementsReliance on partnership discussions and contingent financing sources to fund key clinical milestones introduces execution uncertainty and could increase share‑price volatility if deals or capital raises do not materialize as expected.
Financing And Dilution RiskLimited cash on hand is prompting plans for equity raises, at‑the‑market offerings and warrant exercises, which could dilute existing shareholders and pressure the stock if sizeable financing is required.
Operational Runway And Trial ExecutionCareful control of spending remains necessary to support continued patient enrollment and site activation, creating risk that cost constraints could delay trial operations or slow enrollment momentum.
Imunon News
IMNN FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was $2.52 and its highest was $41.22 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $11.61M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is May 18, 2026 which is in 33 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Mar 31, 2026. The company reported -$1.241 earnings per share for the quarter, missing the consensus estimate of -$0.873 by -$0.368.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imunon have?
Imunon has 3,922,764 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$1.241 in its last earnings report, missing expectations of -$0.873. Following the earnings report the stock price went up 2.083%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in IMNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
IMNN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed strong, potentially transformative clinical momentum driven by a robust Phase II overall survival signal (14.7 months) and faster-than-expected Phase III enrollment, supported by translational data, publications, CRO support and cost discipline. However, near-term financing risk is acute (cash of $8.8M with runway into H2 2026), the registrational timeline extends to 2029 absent an early interim readout, and some scientific endpoints (MRD) remain exploratory. Management is actively pursuing financing and partnerships and has taken cost-saving measures to extend the runway, but successful execution of funding and completion of the Phase III program are critical next steps.View all IMNN earnings summariesIMNN Stock 12 Month Forecast
Average Price Target
$18.50
▲(525.00% Upside)
Technical Analysis
Ownership Overview
11.04% Insiders
1.22% Mutual Funds
10.59% Other Institutional Investors
76.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---